Chew on this: Co. launches stress-suppressing gum

NEW YORK Ventana Biotech on Friday announced that it is conducting research in developing a Stress Suppressing Chewing Gum.

A preliminary estimate of the royalty cash-flow from a successful stress-suppressing drug is $1.6 billion to $1.9 billion over a 10 year period, the company estimated.

According to the company, more Americans are suffering from chronic stress, a condition that could lead to a diagnosis of post-traumatic stress disorder.